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Background: Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease, with very little
improvement in survival over the past 50 years. Recent large-scale genomic studies have improved
understanding of the genomic and transcriptomic landscape of the disease, yet very little is known about
molecular heterogeneity according to tumour location in the pancreas; body and tail PDACs especially
tend to have a significantly worse prognosis. The aimwas to investigate themolecular differences between
PDAC of the head and those of the body and tail of the pancreas.
Methods: Detailed correlative analysis of clinicopathological variables, including tumour location,
genomic and transcriptomic data, was performed using the Australian Pancreatic Cancer Genome Ini-
tiative (APGI) cohort, part of the International Cancer Genome Consortium study.
Results: Clinicopathological data were available for 518 patients recruited to the APGI, of whom 421
underwent genomic analyses; 179 of these patients underwent whole-genome and 96 RNA sequencing.
Patients with tumours of the body and tail had significantly worse survival than those with pancreatic
head tumours (12⋅1 versus 22⋅0months; P= 0⋅001). Location in the body and tail was associated with
the squamous subtype of PDAC. Body and tail PDACs enriched for gene programmes involved in
tumour invasion and epithelial-to-mesenchymal transition, as well as features of poor antitumour immune
response. Whether this is due to a molecular predisposition from the outset, or reflects a later time point
on the tumour molecular clock, requires further investigation using well designed prospective studies in
pancreatic cancer.
Conclusion: PDACs of the body and tail demonstrate aggressive tumour biology that may explain worse
clinical outcomes.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is expected to
become the third leading cause of cancer-related death in
Western societies, and to overtake breast cancer for the first
time in 20171. The 5-year survival rate, almost unchanged
in 50 years, remains less than 10 per cent1. Surgical resec-
tion is the only chance of cure, with chemotherapy adding
modest benefit to overall survival2–4. Early recurrence
remains a major clinical concern for patients undergoing
pancreatectomy, and accurate preoperative prognostication
is currently a challenge.
Numerous studies5–9 have demonstrated meaningful
differences in outcome of pancreatic cancers located in
the head, compared with those of the body and tail.
Approximately 15 per cent of PDACs occur in the body
and tail, and differences in outcome have been largely
attributed to late presentation in comparison with tumours
of the pancreatic head5–7,9. Tumours of the head and unci-
nate process often present with jaundice, and are therefore
thought to present earlier in the disease process. Body and
tail pancreatic cancer usually presents with weight loss and
pain, symptoms more in keeping with advanced disease7.
Yet, previous data suggest that TNM stage at presenta-
tion is not significantly different between the two tumour
locations10.
Recent large-scale sequencing studies11–16 have demon-
strated that PDAC harbours significant interpatient
genomic heterogeneity. Apart from a few well known
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mutations that are currently not targetable (KRAS, TP53,
CDKN2A and the loss of SMAD4), most genetic aber-
rations occur at low frequency (10 per cent or less).
Whole-genome sequencing of 100 resected PDACs
demonstrated unique structural variation subtypes based
on chromosomal rearrangement numbers and patterns that
appear to predict response to platinum-based chemother-
apy in a ‘synthetic lethality’ manner13. Additionally,
integrated genomic analyses14–16 revealed distinct molecu-
lar subtypes of PDAC based on transcriptomic profiles that
correspond to clinical outcomes. Bailey and colleagues14
described a poor prognostic ‘squamous’ subtype that is
enriched for histopathological adenosquamous tumours,
TP53 mutations17, and gene programmes associated with
inflammation, hypoxia response, metabolic reprogram-
ming, MYC pathway activation and transforming growth
factor β signalling14. The squamous subtype was enriched
for gene programmes that are common in squamous-like
tumours of breast, bladder, lung, and head and neck
cancer18; and characterized by hypermethylation and
downregulation of genes involved in pancreatic endoder-
mal differentiation (PDX1, MNX1, GATA6, HNF1B)14. In
addition, the squamous subtype was enriched for mutations
and loss of key epigenetic regulators (such as KDM6A)
and this may contribute to the loss of endodermal prop-
erties of these tumours14. Expression patterns of immune
cell populations within the tumour microenvironment
demonstrated unique differences between transcriptomic
subtypes, with evidence of immune avoidance in the
squamous subtype14.
The molecular pathology of PDAC has recently been
studied intensely, yet the exact genetic and molecular dif-
ferences between PDACs of the head and those of the
body and tail have not been fully elucidated. Therefore,
the aim of this study was to explore and define the genomic
and transcriptomic differences between head and body/tail
PDAC based on a large integrated genomic analysis of
PDAC14.
Methods
Patients were recruited prospectively through the Aus-
tralian Pancreatic Cancer Genome Initiative (APGI) as
part of the International Cancer Genome Consortium
(ICGC). Informed consent and human research ethics
approvals were obtained from each contributing clinical
centre (Appendix S1, supporting information). Con-
tributing patients were restricted to those with resectable,
chemotherapy- and radiotherapy-naïve PDAC, who under-
went either Whipple’s pancreatoduodenectomy, or total
or distal pancreatectomy. Following surgical resection,
histopathological analysis was performed by a pancreatic
pathologist. Specimens with macroscopic evidence of
tumour were snap-frozen as a source of tumour DNA,
along with samples of duodenum, stomach or spleen as
a source of germline DNA. Standard histopathological
processing was undertaken, and a diagnosis of PDAC was
confirmed independently by two consultant pathologists
with a specialist interest in pancreatic cancer. Fresh-frozen
tumour samples underwent full-face cryosection to con-
firm the presence of tumour and to estimate epithelial
cellularity. Macrodissection was performed before DNA
and RNA extraction to enrich for tumour epithelium.
DNA and RNA extraction was carried out using the All-
Prep Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol.
Data analysis
Whole-exome and/or whole-genome andRNA sequencing
was performed and analysed as described previously12–14.
Briefly, genome sequence data were aligned and mapped
using the Genome Reference Consortium GRCh37
assembly, and the Burrows–Wheeler alignment tool19.
Single-nucleotide substitutions and insertions/deletions,
structural variations, copy number analysis, mutational sig-
nature and RNA sequencing analysis was carried out12–14.
Hierarchical clustering, gene set and pathway enrichment
analysis was performed using the R package (R Project for
Statistical Computing, Vienna, Austria)14.
Statistical analysis
Disease-specific survival was used for all survival analy-
ses. Median survival was estimated by the Kaplan–Meier
method, and differences tested using the log rank test20.
P< 0⋅050 was considered statistically significant. Clinico-
pathological variables with P< 0⋅100 on log rank testing
were entered into a Cox proportional hazards multivariable
analysis21. Statistical analysis was performed using SPSS®
version 22.0 (IBM, Armonk, New York, USA) and R 3.3.1.
Results
Patient characteristics are summarized in Table 1 and
Table S1 (supporting information). In total 518 patients
with detailed clinical and pathological data were identified;
421 PDACs underwent DNA sequencing, consisting of
179 whole genomes and 242 whole exomes. Ninety-six
patients underwent whole-transcriptome RNA sequencing
and another 266 underwent transcriptomic characteriza-
tion based on microarray gene expression analysis owing
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Table 1 Characteristics of patients in the Australian Pancreatic Cancer Genome Initiative cohort who underwent resection of pancreatic
ductal adenocarcinoma according to tumour location
Head Body and tail
No. of patients* (n=426) Median DSS (months) P‡ No. of patients* (n=92) Median DSS (months) P‡
Age (years)† 68⋅0 (28⋅0–88⋅0) 70⋅5 (28⋅0–86⋅0)
Mean 66⋅5 67⋅8
Sex ratio (M : F) 213 : 213 0⋅904 45 : 47 0⋅168
Outcome
Follow-up (months)† 48 (18–164) 45 (32–136)
Died
Pancreatic cancer 196 (46⋅0) 47 (51)
Other 10 (2⋅3) 5 (5)
Unknown 0 (0) 0 (0)
Alive 215 (50⋅5) 40 (43)
Lost to follow-up 5 (1⋅2) 0 (0)
Tumour stage < 0⋅001 0⋅018
I 24 (5⋅6) 56⋅6 8 (9) 51⋅9
II 400 (93⋅9) 21⋅0 74 (80) 13⋅0
III 1 (0⋅2) 20⋅0 1 (1) 21⋅0
IV 1 (0⋅2) 5⋅7 9 (10) 7⋅6
T category 0⋅117 0⋅142
T1 16 (3⋅8) 31⋅0 5 (5) 73⋅0
T2 34 (8⋅0) 32⋅0 14 (15) 15⋅8
T3 375 (88⋅0) 21⋅0 72 (78) 11⋅6
T4 1 (0⋅2) 20⋅0 1 (1) 21⋅0
N category 0⋅004 0⋅724
N0 134 (31⋅5) 25⋅2 35 (39) 12⋅0
N1 292 (68⋅5) 20⋅7 55 (61) 13⋅0
Tumour grade 0⋅012 0⋅903
I 32 (7⋅5) 38⋅1 9 (10) 15⋅8
II 283 (66⋅6) 23⋅0 57 (63) 12⋅1
III 107 (25⋅2) 17⋅0 23 (25) 13⋅0
IV 3 (0⋅7) 13⋅0 2 (2) 9⋅0
Tumour size (mm) 0⋅005 0⋅004
≤ 20 92 (21⋅6) 32⋅0 9 (10) 72⋅6
> 20 333 (78⋅4) 19⋅0 80 (87) 12⋅0
Surgical margins (R0= 0mm) < 0⋅001 0⋅152
Clear 285 (66⋅9) 25⋅2 53 (58) 14⋅0
Involved 141 (33⋅1) 16⋅7 39 (42) 11⋅4
Perineural invasion 0⋅020 0⋅556
No 94 (22⋅5) 29⋅7 20 (22) 13⋅0
Yes 324 (77⋅5) 20⋅0 69 (78) 12⋅1
Vascular invasion 0⋅002 0⋅045
No 193 (46⋅8) 25⋅0 41 (47) 15⋅4
Yes 219 (53⋅2) 19⋅4 46 (53) 11⋅6
Adjuvant chemotherapy < 0⋅001 0⋅013
< 3 cycles 249 (58⋅7) 16⋅5 61 (66) 9⋅3
≥ 3 cycles 175 (41⋅3) 29⋅9 31 (34) 17⋅0
*With percentages in parentheses unless indicated otherwise; †values are median (range). Data were missing for some variables. DSS, disease-specific
survival. ‡Log rank test.
to lower tumour epithelial content, of whom 262 had
survival data available for analysis (Table S1, supporting
information).
Prognosis after pancreatectomy in relation
to tumour location
In the APGI cohort, the majority of tumours (426,
82⋅2 per cent) were located in the head of the pancreas
and 92 (17⋅8 per cent) presented with body and tail
pancreatic cancer. There was no difference in patient
demographics between those presenting with head versus
body/tail tumours (Table 1). Body and tail pancreatic
cancers were more likely to be of lower pathological T
category (T1–2) (21 versus 11⋅7 per cent; P= 0⋅021), yet
significantly larger at the time of resection (P= 0⋅007)
(Table S2, supporting information). Although there was no
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Table 2 Association between tumour location and Bailey subtype
Non-squamous Squamous P*
RNA sequencing cohort (n=96) 0⋅033
Head 60 (85) 16 (64)
Body/tail 11 (15) 9 (36)
Microarray cohort (n=266) < 0⋅001
Head 163 (88⋅6) 57 (70)
Body/tail 21 (11⋅4) 25 (30)
Values in parentheses are percentages. *χ2 test.
discernible difference in well known prognostic pathologi-
cal variables between the two groups (Table S2, supporting
information), survival was significantly worse in patients
presenting with body and tail tumours (median survival
12⋅1 versus 22⋅0months; P= 0⋅001) (Fig. S1A, supporting
information). This remained significant in multivariable
analysis (hazard ratio 1⋅72, 95 per cent c.i. 1⋅31 to 2⋅26;
P< 0⋅001) (Table S3, supporting information).
Association between body and tail cancers
and squamous subtype
Cancers of the body and tail of pancreas co-segregated with
the squamous subtype of pancreatic cancer, both among
patients who underwent whole-transcriptome sequencing
(96 patients; P= 0⋅033) and those who underwent mRNA
microarray sequencing (non-redundant set, 266 patients;
P< 0⋅001) (Table 2). There was no association between
tumour location and chromosomal structural variation sub-
type (P= 0⋅211) (Table S4, supporting information). How-
ever, body and tail pancreatic cancer was associated with a
BRCAmutational signature (Catalogue of Mutational Pro-
cesses in Cancer (COSMIC)) (P= 0⋅025) (Table S4, sup-
porting information). Based on the frequency of mutations
per megabase, COSMIC mutational signature 8 (unknown
aetiology) was associated with tumour location (P= 0⋅002),
but not signatures associated with loss of mismatch repair
status (P= 0⋅619), oesophageal cancer (COSMIC muta-
tional signature 17) (P= 0⋅976), deamination (P= 0⋅287)
and apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like (APOBEC) (P= 0⋅301).
Association between squamous subtype, tumour
grade and recurrence
In view of the significant association between the poor
prognostic squamous subtype and body and tail pancreatic
cancer, a detailed clinical and pathological analysis of the
squamous subtype was undertaken in 96 patients who
underwent whole-transcriptome sequencing as part of the
ICGC project. This demonstrated a significant associa-
tion with poor tumour differentiation and higher tumour
Table 3 Association between clinicopathological variables,
tumour recurrence patterns and pancreatic adenocarcinoma
subtype based on RNA sequencing set
Non-squamous
(n=71)
Squamous
(n=25) P†
T category 0⋅467
T1–2 11 (16) 3 (12)
T3–4 59 (84) 22 (88)
N category 0⋅520
N0 25 (36) 8 (33)
N1 45 (64) 16 (67)
Tumour grade/differentiation < 0⋅001
I/II 52 (74) 5 (22)
III/IV 18 (26) 18 (78)
Perineural invasion 0⋅027
No 9 (13) 8 (35)
Yes 59 (87) 15 (65)
Vascular invasion 0⋅256
No 31 (46) 8 (35)
Yes 37 (54) 15 (65)
Tumour size (mm) 0⋅185
≤ 20 10 (14) 1 (4)
> 20 60 (86) 22 (96)
Surgical margin 0⋅615
Negative 58 (83) 20 (83)
Positive 12 (17) 4 (17)
Histological subtype 0⋅014
IPMN with invasion 13 (18) 0 (0)
PDAC – NOS 58 (82) 25 (100)
Local recurrence* 0⋅194
No 37 (90) 20 (100)
Yes 4 (10) 0 (0)
Liver recurrence* 0⋅002
No 25 (56) 3 (15)
Yes 20 (44) 17 (85)
Lung recurrence* 0⋅345
No 33 (73) 13 (65)
Yes 12 (27) 7 (35)
Lung recurrence (not liver)* 0⋅432
No 38 (84) 18 (90)
Yes 7 (16) 2 (10)
Non-liver distant recurrence* 0⋅040
No 27 (66) 18 (90)
Yes 14 (34) 2 (10)
Values in parentheses are percentages. Data were missing for some
variables. *Recurrence data shown only for patients who developed any
recurrence during the study interval. †χ2 test. IPMN, intraductal
papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma;
NOS, not otherwise specified.
grade (P< 0⋅001), but not with pathological T category
(P= 0⋅467), node status (P= 0⋅520) or surgical margin sta-
tus (P= 0⋅615) (Table 3). These findings were recapitulated
in the microarray set (Table S5, supporting information).
The squamous subtype was associated significantly with
liver recurrence (P= 0⋅002) (Table 3), and liver recurrence
was associated with significantly worse survival compared
with local and other distant recurrence patterns (median
survival 13⋅6 versus 20⋅0months respectively; P< 0⋅001)
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: e183–e191
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Fig. 1 a Association between expression of gene programmes 2, 6 and 8 and tumour location. Median values (bold line), i.q.r. (box) and
range (error bars) are shown. *P< 0⋅050 (Kruskal–Wallis test). b Kaplan–Meier curve showing survival according to Bailey subtype and
tumour location in 94 patients from the RNA sequencing set. P= 0⋅010 (log rank test). cHeatmap of relative gene expression within
gene programme 2 demonstrating strong correlation between squamous subtype, body and tail tumours, and gene programme 2
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Fig. 2 Graphical representation of the association between pancreatic adenocarcinoma location and differential transcriptional networks
in the Australian Pancreatic Cancer Genome Initiative cohort. A potential theory of subtype evolution suggests that tumour size
increases along the molecular clock, associated with dedifferentiation from pancreatic progenitor-like to squamous-like. EMT,
epithelial-to-mesenchymal transition
(Fig. S1B, supporting information), regardless of primary
tumour location. Furthermore, all 20 patients with squa-
mous tumours that had developed recurrence during
follow-up died from distant metastatic disease (Table 3).
There was no association between lung recurrence and
transcriptomic subtypes (P= 0⋅345).
Prognosis in relation to tumour location
and squamous subtype
Kaplan–Meier survival analysis demonstrated that patients
with the squamous subtype of PDAC had a signifi-
cantly worse prognosis in the RNAseq set (median
survival 13⋅3months versus 23⋅7months in those with
non-squamous tumours; P= 0⋅010) (Fig. S1C, supporting
information). Resected tumours were segregated into
tumour location and transcriptomic subtype, as defined
in Bailey et al.14, to assess the difference in prognosis
in squamous tumours of the head or body and tail.
Patients who had squamous tumours of the body and tail
had an extremely poor survival compared with the rest
of the cohort (median survival 5⋅2 versus 22⋅0months;
P< 0⋅001) (Fig. 1b). These findings were recapitulated in
the microarray set (median survival 25⋅0, 18⋅4, 15⋅9 and
11⋅5months among patients with non-squamous tumours
of the head, squamous tumours of the head, non-squamous
tumours of the body/tail and squamous tumours of the
body/tail respectively; P= 0⋅001) (Fig. S1D, supporting
information).
The prognostic value of mutational signatures was
assessed against the APGI cohort in 167 patients who
underwent whole-genome sequencing and had sufficient
clinical data available for analysis. There was no relation-
ship between mutational signatures associated with loss
of mismatch repair (P= 0⋅573), signature 8 (unknown
aetiology) (P= 0⋅227), signature 17 (oesophageal can-
cer) (P= 0⋅639), deamination (P= 0⋅716), APOBEC
(P= 0⋅899) or BRCA (P= 0⋅575) and survival in patients
with resected PDAC.
Association between body and tail pancreatic
cancer and molecular features of aggressive disease
An in-depth analysis of tumour location in relation to gene
programmes that define the Bailey subtypes was under-
taken. Body and tail pancreatic cancer was significantly
associated with gene networks involved in epithelial-to-
mesenchymal transition (EMT), inflammation, hypoxia
response, metabolic reprogramming, TP63 expression and
squamous differentiation (gene programme 2) (Fig. 1a)14.
Conversely, head tumours were enriched for gene pro-
grammes 6 and 8, which are associated with B cell and
CD8-positive T cell signalling respectively14 (Fig. 1;
Table S6, and Figs S2 and S3, supporting information). Body
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and tail pancreatic cancer exhibited immune signatures
corresponding to low dendritic cell infiltrate (P= 0⋅005),
low co-stimulation of antigen-presenting cells (P= 0⋅041)
and a low type II interferon response (P= 0⋅002) (Table S6,
supporting information). These findings suggest that,
relative to pancreatic head cancer, body and tail tumours
are associated with more aggressive disease biology and
potentially exhibit a dampened antitumour immune
response and increased immune avoidance.
Discussion
Clinical outcomes for body and tail pancreatic cancer
appear to be significantly worse in both the resectable and
advanced disease stages. The present study has demon-
strated distinct molecular differences between resectable
PDAC from the head and body/tail. Body and tail pan-
creatic cancer is associated with the squamous subtype
of pancreatic cancer and enriched for gene programmes
associated with inflammation, EMT and potential immune
avoidance mechanisms.
The temporal sequence of genomic and epigenomic
events leading to the progression to different PDAC sub-
types has yet to be fully elucidated. However, the squamous
subtype appears to be more advanced on the molecular
clock than other subtypes, and this may reflect an addi-
tional level of genomic instability, owing to the accumula-
tion of DNA damage, and molecular events that contribute
to the unique transcriptome of these tumours14. Previous
studies14–16 have found that these tumours are enriched for
epigenetic events leading to hypermethylation and down-
regulation of genes involved in pancreatic development,
and enriched for molecular drivers of EMT. The present
results suggest that body and tail pancreatic cancer is more
likely to be of a squamous subtype, suggesting that these
are biologically more aggressive at the time of diagnosis, or
surgical resection, than cancers of the pancreatic head. The
results also suggest that the squamous subtype of PDAC is
associated predominantly with liver recurrence; this may
in part explain the worse prognosis of patients with liver
metastases compared with those with metastases at other
distant sites22. In this cohort, none of the intraductal papil-
lary mucinous neoplasm-related PDACs were classified as
the squamous subtype (Table 3), potentially revealing a dif-
ferent carcinogenesis pathway for the squamous subtype14.
The squamous subtype correlates with increased size and
poor tumour differentiation, which may reflect tumours
that present at a later stage, or have an accelerated de-
differentiation pathway (Fig. 2).
Transcriptomic subtyping of PDAC remains a debated
topic, and it has recently been suggested that there
is significant overlap between the squamous sub-
type described by Bailey et al.14, and the basal16 and
quasi-mesenchymal15 classifications. The role of stromal
factors and immune infiltrate remains crucial to tumour
growth and response to therapy, and is likely to remain a
crucial aspect of molecular subtyping in PDAC14,16. As a
result, the implications of tumour cellularity on transcrip-
tomic analysis remain a priority area of research. However,
several studies23–25 have demonstrated that epithelial cell
lines of PDAC recapitulate published transcriptomic sub-
types, including transcripts native to pancreatic exocrine
and endocrine cells defining an aberrantly differentiated
endocrine exocrine subtype (ADEX).
Genes involved in inflammation, EMT and invasion are
enriched in body and tail pancreatic cancer; these molec-
ular factors are known to be associated with poor prog-
nosis. Levels of mRNA transcripts of calcium-binding
protein S100A2, which accelerates tumour invasion, are
greater in body and tail pancreatic cancer than in cancers
of the pancreatic head, and this is one of the most dif-
ferentially expressed genes in gene programme 2 (Fig. 1).
High S100A2 expression has been shown previously to
be highly prognostic in PDAC, and forms a key molecu-
lar predictor of early recurrence in a preoperative molec-
ular nomogram for operable PDAC (S. B. Dreyer, M.
Pinese, N. B. Jamieson, C. J. McKay, A.V. Biankin, D.
K. Chang et al., unpublished data)26,27. In the RNAseq
cohort here, patients with squamous subtype body and
tail pancreatic cancer had extremely poor survival (median
5⋅2months), in comparison with the rest of the resected
cohort. This suggests that such patients may be better
treated with a neoadjuvant approach as occult metastatic
disease may manifest over this period, and avoid futile
major surgery. Because of the molecular features of aggres-
sive disease associated with body and tail pancreatic can-
cer, it could also be argued that, until molecular markers
of early recurrence are better defined, all body and tail
tumours are better served with a neoadjuvant approach
to identify patients whose tumours are likely to recur
early.
It has been demonstrated here that head tumours are
relatively enriched for B cell signalling (gene programme
6) and this has been shown to be associated with a better
prognosis14. Similarly, body and tail pancreatic cancer lacks
CD8-positive T cell signalling (gene programme 8), sug-
gesting an immunosuppressive tumour microenvironment.
This may well reflect an increase in myeloid cell infiltra-
tion and tumour-associated macrophage-related immuno-
suppression and inflammation28. In-depth analysis of the
tumour microenvironment may reveal potential targets for
novel immunotherapy agents in body and tail pancreatic
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: e183–e191
on behalf of BJS Society Ltd.
e190 S. B. Dreyer, N. B. Jamieson, R. Upstill-Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
cancer, including the immune checkpoint and myeloid sig-
nalling axes28.
It remains to be determined whether body and tail
pancreatic cancer presents at a later stage of tumour
evolution, or whether these tumours are biologically dif-
ferent and more aggressive from the outset. However,
some of the present findings seem to reflect the relatively
late presentation of body and tail pancreatic cancer at
a more advanced stage, both clinically and molecularly
(Fig. 2). First, tumours of the body and tail are larger,
which may reflect a biologically older tumour. Second,
body and tail pancreatic cancers correlate with molecular
features that are driven by epigenetic events associated
with chromosomal instability and epigenetic events that
may drive intratumoral heterogeneity29,30. The exact
sequence of these events in tumorigenesis and progression
has yet to be elucidated, but may be associated with a later
stage of disease evolution.
Identifying patients who will benefit from procedures
with high morbidity rates such as pancreatectomy is an
important task for surgeons. Personalized medicine plat-
forms, such as Precision Panc31, will allow clinicians and
scientists to correlate molecular profiles with clinicopatho-
logical outcomes, as well as define and refine molecular
subgroups that respond to personalized treatment regi-
mens, including surgery. Well designed clinical trials, par-
ticularly in the operable and neoadjuvant setting, will allow
detailed study of the temporal and spatial clonal evolution
of PDAC, and may shed light on the relationship between
disease progression and the molecular timeline of tumours.
This will contribute to an expanding knowledge bank of
molecular and clinical data, acquired from multiple initia-
tives globally, and will further delineate the relationship
between tumour location, stage at presentation and the
molecular features of PDAC.
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